Jor­dan­ian OTC drug man­u­fac­tur­er re­ceives FDA warn­ing let­ter over mul­ti­ple ‘un­ac­cept­able haz­ards’

Gener­ic drug man­u­fac­tur­er Am­man Phar­ma­ceu­ti­cal In­dus­tries has been is­sued an FDA warn­ing let­ter af­ter be­ing placed on sev­er­al im­port alerts, with in­spec­tors find­ing “fun­da­men­tal de­sign flaws” and “se­ri­ous da­ta breach­es” at its fa­cil­i­ty in Jor­dan’s cap­i­tal.

The FDA not­ed the fa­cil­i­ty had “un­ac­cept­able con­di­tions” which can lead to drug con­t­a­m­i­na­tion.

The warn­ing let­ter — hand­ed to Am­man on Feb. 14 — was pub­lished on Feb. 26. The man­u­fac­tur­er ships over-the-counter med­i­cines glob­al­ly, in­clud­ing to the US.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER